Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability
of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients
with selected advanced malignancies, who are ineligible for or there are no available
therapies known to confer a clinical benefit for their disease, or they have exhausted all
such available options in each indication and therefore will be patients for whom a clinical
trial is appropriate.